Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palisade Bio Inc PALI

Healthcare Biotechnology
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD... see more

Recent & Breaking News (NDAQ:PALI)

Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update

GlobeNewswire November 13, 2017

Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

GlobeNewswire November 8, 2017

Technical Insights on Biotech Stocks -- Celsion, Corcept Therapeutics, ContraVir Pharma, and Neuralstem

PR Newswire October 25, 2017

The Week Ahead: Earnings Season Starts In Earnest

Benzinga.com  October 23, 2017

Neuralstem Announces the Appointment of Two New Members to the Board of Directors

GlobeNewswire September 25, 2017

Neuralstem Announces Issuance of Two U.S. Patents

GlobeNewswire September 7, 2017

Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update

GlobeNewswire August 8, 2017

Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy

GlobeNewswire August 2, 2017

Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants

GlobeNewswire July 27, 2017

Neuralstem Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire July 26, 2017

Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder

GlobeNewswire July 25, 2017

Neuralstem Added to the Russell Microcap® Index

GlobeNewswire June 26, 2017

Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder

GlobeNewswire May 17, 2017

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update

GlobeNewswire May 10, 2017

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

GlobeNewswire April 12, 2017

How These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences

PR Newswire March 27, 2017

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

GlobeNewswire March 23, 2017

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

GlobeNewswire March 17, 2017

Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury

GlobeNewswire March 9, 2017

Neuralstem to Present at 29th Annual ROTH Conference

GlobeNewswire March 8, 2017